Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 637-646

  De Backer, L A ^a   Vos, W G ^a   Salgado, R ^a   de Backer, J W ^a   Devolder, A ^a   Verhulst, S L ^a   Claes, R ^a   Germonpre P R ^a   de Backer, W A ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Computational fluid dynamics; Computed tomography; Imaging; Ipratropium; Salbutamol

Indexed keywords

IPRATROPIUM BROMIDE; SALBUTAMOL; BRONCHODILATING AGENT;

ADULT; AGED; AIRWAY RESISTANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTATIONAL FLUID DYNAMICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE ANALYSIS; LUNG FUNCTION TEST; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PILOT STUDY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SYNDROME DELINEATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; HYDRODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; FEMALE; HUMANS; HYDRODYNAMICS; IPRATROPIUM; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84859263440     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S21917     Document Type: Article

References (36)

1. Bosken CH, Wiggs BR, Pare PD, Hogg JC. Small airway dimensions in smokers with obstruction to airfow. Am Rev Respir Dis. 1990;142(3):563-570.
2. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148(5):1220-1225.
3. Pare PD, Brooks LA, Coppin CA, et al. Density-dependence of maximal expiratory flow and its correlation with small airway disease in smokers. Am Rev Respir Dis. 1985;131(4):521-526.
4. Walker P P, Calverley PM. The volumetric response to broncho-dilators in stable chronic obstructive pulmonary disease. COPD. 2008;5(3):147-152.
5. Burns G P, Gibson GJ. A novel hypothesis to explain the bronch-constrictor effect of deep inspiration in asthma. Thorax. 2002;57(2): 116-119.
6. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinfation. Chest. 2002;121(4):1042-1050.
7. Grenier PA, Beigelman-Aubry C, Fetita C, Preteux F, Brauner M W, Lenoir S. New frontiers in CT imaging of airway disease. Eur Radiol. 2002;12(5):1022-1044.
8. Gevenois PA, Yernault JC. Can computed tomography quantify pulmonary emphysema? Eur Respir J. 1995;8(5):843-848.
9. Achenbach T, Weinheimer O, Biedermann A, et al. MDCT assessment of airway wall thickness in COPD patients using a new method: Correlations with pulmonary function tests. Eur Radiol. 2008;18(12):2731-2738.
10. Brillet PY, Fetita CI, Saragaglia A, et al. Investigation of airways using MDCT for visual and quantitative assessment in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):97-107.
11. De Luca N, Capuzi P, D'Angeli AL, et al. High resolution computed tomography (HRCT) assessment of beta 2-agonist induced bronchodila-tion in chronic obstructive pulmonary disease patients. Eur Rev Med Pharmacol Sci. 1999;3(2):83-87.
12. Hasegawa M, Makita H, Nasuhara Y, et al. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax. 2009;64(4): 332-338.
13. Longest P W, Vinchurkar S. Effects of mesh style and grid convergence on particle deposition in bifurcating airway models with comparisons to experimental data. Med Eng Phys. 2007;29(3):350-366.
14. Yang XL, Liu Y, So RM, Yang JM. The effect of inlet velocity profile on the bifurcation COPD airway fow. Comput Biol Med. 2006;36(2):181-194.
15. Ma B, Lutchen KR. CFD simulation of aerosol deposition in an anatomically based human large-medium airway model. Ann Biomed Eng. 2009;37(2):271-285.
16. 3He magnetic resonance phase-contrast velocimetry. J Appl Physiol. 2007;102(5):2012-2023.
17. Lin CL, Tawhai M, McLennan G, Hoffman E. Computational fluid dynamics. IEEE Eng Med Biol Mag. 2009;28(3):25-33.
18. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533(1-3):36-39.
19. McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:CD003900.
20. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest. 2003;123(6):1810-1816.
21. Brusasco V, Crapo R, Viegi G. Coming together: The ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J. 2005;26(1):1-2.
22. De Backer J W, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257(3):854-862.
23. De Backer JW, Vos WG, Burnell P, et al. Study of the variability in upper and lower airway morphology in Sprague-Dawley rats using modern micro-CT scan-based segmentation techniques. Anat Rec (Hoboken). 2009;292(5):720-727.
24. De Backer JW, Vos WG, Gorle CD, et al. Flow analyses in the lower airways: Patient-specific model and boundary conditions. Med Eng Phys. 2008;30(7):872-879.
25. De Backer JW, Vos WG, Devolder A, et al. Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation. J Biomech. 2008;41(1): 106-113.
26. Netter FH. Respiratory System. Summit, NJ: CIBA Collection; 1979.
27. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Broncho-dilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659-664.
28. Tashkin D P, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31(4):742-750.
29. Ben SH, Prefaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from GOLD: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther. 2008;21(5):767-773.
30. Schermer T, Heijdra Y, Zadel S, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med. 2007;101(6):1355-1362.
31. Kurashima K, Takayanagi N, Sato N, et al. High resolution CT and bronchial reversibility test for diagnosing COPD. Respirology. 2005;10(3):316-322.
32. Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D. Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol. 2005;59(4):379-384.
33. Teale C, Morrison JF, Page RL, Pearson SB. Dose response to inhaled salbutamol in chronic obstructive airways disease. Postgrad Med J. 1991;67(790):754-756.
34. Cazzola M, Santus P, D'Adda A, Pizzolato S, DiMarco F, Centanni S. Acute effects of higher than standard doses of salbutamol and iprat-ropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulm Pharmacol Ther. 2009;22(3):177-182.
35. Kim WJ, Hersh CP, DeMeo DL, Reilly JJ, Silverman EK. Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir Med. 2009;103(4):552-557.
36. Umeda N, Yoshikawa T, Kanazawa H, Hirata K, Fujimoto S. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology. 2008;13(3):346-352.